Pseudomonas aeruginosa serious infections: Mono or combination antimicrobial therapy?

Matteo Bassetti, Elda Righi, Claudio Viscoli

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

P. aeruginosa is a serious cause of infection with reported rates of mortality being up to 61%. Several studies evidenced a correlation between hospital mortality due to P. aeruginosa bloodstream infections and an inappropriate antimicrobial treatment. Increasing resistance in P. aeruginosa isolates complicates the selection of adequate empirical therapy in severe infections and P. aeruginova is often indistinguishable from other gram-negative bacterial infections. For these reasons, present guidelines for the treatment of suspected P. aeruginosa bacteraernia recommend the rapid introduction of empirical antimicrobial therapy that includes at least one antipseudomonal agent until having microbiological results. Current consensus favours the use of empirical combination, balancing the potential for greater toxicity against the lower emergence of antimicrobial resistance and the greater killing that might be achieved by combination therapies acting synergistically. Advantages and disadvantages of combination therapy towards monotherapy for P. aeruginosa severe infections, current antibiotics used for P. aeruginosa severe infections and main studies published on this issue are reviewed.

Original languageEnglish
Pages (from-to)517-522
Number of pages6
JournalCurrent Medicinal Chemistry
Volume15
Issue number5
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Pseudomonas aeruginosa
Toxicity
Anti-Bacterial Agents
Infection
Therapeutics
Gram-Negative Bacterial Infections
Hospital Mortality
Guidelines
Mortality

Keywords

  • Aminoglycosides
  • Antibiotic
  • Beta-lactam
  • Combination
  • Flouroquinolones
  • Infection
  • P. aeruginosa
  • Treatment

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Pseudomonas aeruginosa serious infections : Mono or combination antimicrobial therapy? / Bassetti, Matteo; Righi, Elda; Viscoli, Claudio.

In: Current Medicinal Chemistry, Vol. 15, No. 5, 02.2008, p. 517-522.

Research output: Contribution to journalArticle

@article{7df48deb3bcf433aa7817095b0929445,
title = "Pseudomonas aeruginosa serious infections: Mono or combination antimicrobial therapy?",
abstract = "P. aeruginosa is a serious cause of infection with reported rates of mortality being up to 61{\%}. Several studies evidenced a correlation between hospital mortality due to P. aeruginosa bloodstream infections and an inappropriate antimicrobial treatment. Increasing resistance in P. aeruginosa isolates complicates the selection of adequate empirical therapy in severe infections and P. aeruginova is often indistinguishable from other gram-negative bacterial infections. For these reasons, present guidelines for the treatment of suspected P. aeruginosa bacteraernia recommend the rapid introduction of empirical antimicrobial therapy that includes at least one antipseudomonal agent until having microbiological results. Current consensus favours the use of empirical combination, balancing the potential for greater toxicity against the lower emergence of antimicrobial resistance and the greater killing that might be achieved by combination therapies acting synergistically. Advantages and disadvantages of combination therapy towards monotherapy for P. aeruginosa severe infections, current antibiotics used for P. aeruginosa severe infections and main studies published on this issue are reviewed.",
keywords = "Aminoglycosides, Antibiotic, Beta-lactam, Combination, Flouroquinolones, Infection, P. aeruginosa, Treatment",
author = "Matteo Bassetti and Elda Righi and Claudio Viscoli",
year = "2008",
month = "2",
doi = "10.2174/092986708783503186",
language = "English",
volume = "15",
pages = "517--522",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Pseudomonas aeruginosa serious infections

T2 - Mono or combination antimicrobial therapy?

AU - Bassetti, Matteo

AU - Righi, Elda

AU - Viscoli, Claudio

PY - 2008/2

Y1 - 2008/2

N2 - P. aeruginosa is a serious cause of infection with reported rates of mortality being up to 61%. Several studies evidenced a correlation between hospital mortality due to P. aeruginosa bloodstream infections and an inappropriate antimicrobial treatment. Increasing resistance in P. aeruginosa isolates complicates the selection of adequate empirical therapy in severe infections and P. aeruginova is often indistinguishable from other gram-negative bacterial infections. For these reasons, present guidelines for the treatment of suspected P. aeruginosa bacteraernia recommend the rapid introduction of empirical antimicrobial therapy that includes at least one antipseudomonal agent until having microbiological results. Current consensus favours the use of empirical combination, balancing the potential for greater toxicity against the lower emergence of antimicrobial resistance and the greater killing that might be achieved by combination therapies acting synergistically. Advantages and disadvantages of combination therapy towards monotherapy for P. aeruginosa severe infections, current antibiotics used for P. aeruginosa severe infections and main studies published on this issue are reviewed.

AB - P. aeruginosa is a serious cause of infection with reported rates of mortality being up to 61%. Several studies evidenced a correlation between hospital mortality due to P. aeruginosa bloodstream infections and an inappropriate antimicrobial treatment. Increasing resistance in P. aeruginosa isolates complicates the selection of adequate empirical therapy in severe infections and P. aeruginova is often indistinguishable from other gram-negative bacterial infections. For these reasons, present guidelines for the treatment of suspected P. aeruginosa bacteraernia recommend the rapid introduction of empirical antimicrobial therapy that includes at least one antipseudomonal agent until having microbiological results. Current consensus favours the use of empirical combination, balancing the potential for greater toxicity against the lower emergence of antimicrobial resistance and the greater killing that might be achieved by combination therapies acting synergistically. Advantages and disadvantages of combination therapy towards monotherapy for P. aeruginosa severe infections, current antibiotics used for P. aeruginosa severe infections and main studies published on this issue are reviewed.

KW - Aminoglycosides

KW - Antibiotic

KW - Beta-lactam

KW - Combination

KW - Flouroquinolones

KW - Infection

KW - P. aeruginosa

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=41549099609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549099609&partnerID=8YFLogxK

U2 - 10.2174/092986708783503186

DO - 10.2174/092986708783503186

M3 - Article

C2 - 18289007

AN - SCOPUS:41549099609

VL - 15

SP - 517

EP - 522

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 5

ER -